Fosbretabulin - Mateon Therapeutics

Drug Profile

Fosbretabulin - Mateon Therapeutics

Alternative Names: CA4DP; CA4P; Combretastatin A-4 phosphate - Mateon Therapeutics; Combretastatin A4 prodrug; Combretastatin-A4; Combretastatin-A4 phosphate; CRC 87-09; CRC-98-09; CS-A4; Fosbretabulin disodium; Fosbretabulin tromethamine; NSC-613729; Zybrestat®

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arizona State University
  • Developer Mateon Therapeutics; National Cancer Institute (USA); OXiGENE; University of Kentucky
  • Class Antineoplastics; Combretastatins; Small molecules; Stilbenes
  • Mechanism of Action Cadherin 5 inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Glioma; Thyroid cancer; Neuroendocrine tumours
  • New Molecular Entity Yes
  • Available For Licensing Yes - Eye disorders; Ovarian cancer

Highest Development Phases

  • Discontinued Age-related macular degeneration; Choroidal neovascularisation; Colorectal cancer; Diabetic retinopathy; Fallopian tube cancer; Gastrointestinal cancer; Head and neck cancer; Leukaemia; Malignant carcinoid syndrome; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Psoriasis; Rheumatoid arthritis; Thyroid cancer

Most Recent Events

  • 05 Dec 2017 Pharmacodynamics data from a preclinical trial in colon cancer released by Mateon Therapeutics
  • 26 Sep 2017 Discontinued - Phase-I for Neuroendocrine tumours (Metastatic disease, Inoperable/Unresectable, Combination therapy, Second-line therapy or greater) in USA (IV)
  • 26 Sep 2017 Discontinued - Phase-I/II for Colorectal cancer in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top